Hims & Hers Stock Dip and What It Means for Telehealth and Clinicians
Monday, March 3, 2025 – ... semaglutide shortage had been resolved. Semaglutide is the active ingredient in weight loss meds like Ozempic and Wegovy, and compounding is legal ...
AbbVie gets into obesity with $350M deal for once-weekly shot | BioPharma Dive
Monday, March 3, 2025 – If successful, these drugs could be used as alternatives to or in combination with marketed drugs like Novo's Wegovy and Lilly's Zepbound to increase ...
How to trick the body’s metabolism: Mouse study reveals new path for weight-loss and diabetes treatments
Monday, March 3, 2025 – Many people who have tried to lose weight by cutting calories are familiar with this frustrating reality: At some point, the body stops shedding pounds. It senses the reduced calorie intake and responds by slowing down metabolism, causing it to burn fewer calories than before the diet.
Semaglutide: A Promising Treatment for Alcohol Use Disorder – INSCMagazine
Monday, March 3, 2025 – Semaglutide, a GLP-1 receptor agonist initially approved for type 2 diabetes and later for weight management, is now showing potential in treating ...
Novo Nordisk Launches National “My Ozempic® Era” Campaign Celebrating Stories of …
Monday, March 3, 2025 – Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg is an injectable prescription medicine used: along with diet and exercise to improve blood ...
Low-carb, low-fibre diets could raise risks of colon cancer – Toronto Star
Monday, March 3, 2025 – Numerous studies have shown that a diet high in sugar and fat — a so-called “Western-style diet” — is linked to colorectal cancer, as well as obesity ...
Targeted drug offers hope for safe, effective senolytic treatment for liver disease, cancer
Monday, March 3, 2025 – ... obesity and diabetes in the region. This chronic liver condition can lead to serious health conditions including severe liver fibrosis or ...
Tesla, Broadcom, Strategy, Coinbase, Robinhood: Stocks to watch today – Quartz
Monday, March 3, 2025 – Eli Lilly wants to replace Zepbound with an even stronger weight loss drug. Nvidia's record earnings reveal just 3 customers make up 30% of revenue.
Semaglutide API Market, Global Outlook and Forecast 2024-2030 – WhaTech
Monday, March 3, 2025 – Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used primarily for the treatment of type 2 diabetes and obesity. The growing ...
Nutrigenomics Market Size, Share and Trends 2025 to 2034 – Precedence Research
Monday, March 3, 2025 – ... cancer, obesity, and cardiovascular diseases. North America has a ... Obesity is a primary application area for nutrigenomics. The obesity ...